

[全部](#)[新闻](#)[图片](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 980,000 条结果（用时 1.17 秒）

[\(5-aminosalicylic acid\) in inflammatory bowel disease - NCBI - NIH](#)

<https://www.ncbi.nlm.nih.gov> › [NCBI](#) › [Literature](#) › [PubMed Central \(PMC\)](#) - [翻译此页](#)

作者: C Williams - 2011 - 被引用次数: 40 - [相关文章](#)

Inflammatory Bowel Disease Research Institute, Cedars-Sinai Medical Centre, Los ... Indeed, much of the recent innovation in **clinical** use of 5-ASA in colitis has come Definitions of **response** and **remission** are quite variable between studies. by **patients** and that it **should** be considered as a viable first-line **therapeutic** ...

缺少字词: ~~clinician~~ expect told

[Current status of monoclonal antibody therapy for the treatment of ...](#)

<https://www.ncbi.nlm.nih.gov> › [NCBI](#) › [Literature](#) › [PubMed Central \(PMC\)](#) - [翻译此页](#)

作者: B Shah - 2010 - 被引用次数: 17 - [相关文章](#)

Inflammatory bowel disease (IBD) includes both Crohn's disease (CD) and ... For the approved agents, seminal **clinical** trials **will** be discussed as well as ... The median **time** to loss of **response** was 38 weeks for infliximab-treated **patients**. ... Adalimumab treatment was superior to placebo at 56 weeks (79% **remission** every ...

缺少字词: ~~clinician~~ told

[\[PDF\] CH39 Page 1-11](#)

www.mhpharmacotherapy.com/1259587487/online_pdfs/CH39_1-11.pdf ▼ [翻译此页](#)

to achieve **disease remission**, students must consider the **patient's** ... related benefits and may be considered if the **patient will** adhere to ... The **patient's** age at the **time** of diagnosis is within that **expected** ... informed of the genetic susceptibility to **inflammatory bowel** **Therapeutic** Alternatives. 3.a. **clinician** if this occurs.

[What to Do When Biologic Agents Are Not Working in Inflammatory ...](#)

www.gastroenterologyandhepatology.net/.../what-to-do-when-biologic-agen... ▼ [翻译此页](#)

作者: SR Dalal - 2015 - 被引用次数: 2 - [相关文章](#)

When **patients** are found to have continued active inflammation despite having ... Secondary loss of **response** may be addressed through strategies such as dose ... Janssen) to treat **inflammatory bowel disease** (IBD) started a revolution in IBD ... a current therapy is effective **should** not be based on **clinical** symptoms alone.

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 34916

Manuscript Type: REVIEW

Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?

Vasudevan A *et al.* Time to response of therapies in inflammatory bowel disease

Abhinav Vasudevan, Peter R Gibson, Daniel R van Langenberg

Abstract

An awareness of the expected time for therapies to induce symptomatic improvement and remission is necessary for determining the timing of follow-up, disease (re)assessment, and the duration to persist with therapies,

Match Overview

1	Internet 15 words crawled on 25-Jul-2012 www.ibd-net.ch	<1%
2	Internet 14 words crawled on 11-Nov-2010 www.dept-med.pitt.edu	<1%
3	Internet 14 words crawled on 18-May-2014 www.dovepress.com	<1%
4	Internet 13 words crawled on 20-Jun-2017 www.wjgnet.com	<1%
5	Internet 11 words crawled on 06-May-2011 www.practicalgastro.com	<1%
6	Internet 11 words crawled on 23-Mar-2010 www.geteccu.org	<1%
7	Internet 11 words crawled on 31-Oct-2016 www.amc.nl	<1%
8	Internet 10 words crawled on 27-May-2014 diyehr.com	<1%
9	Publications 10 words Blonski, Wojciech; Buchner, Anna M. and Lichtenstein, Gary R.. "Once-Daily MMX Mesalamine in the Managem...	<1%

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 77,300 条结果 (用时 0.81 秒)

Progress in the Diagnosis and Treatment of Inflammatory Bowel Disease

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)作者: EV Loftus Jr - 2011 - 被引用次数: 4 - [相关文章](#)

In UC, **intestinal inflammation** is typically restricted to the **colon**, but CD **can** ... these agents have a slow onset of action and a narrow **therapeutic** window. A high proportion of **patients** at Weeks 10 and 54 achieved IBDQ **response** ... **Clinical remission** (defined as Harvey-Bradshaw Index score ≤ 4) was **Time will tell**.

Therapeutic drug monitoring in inflammatory bowel disease - NCBI - NIH

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)作者: U Kopylov - 2014 - 被引用次数: 17 - [相关文章](#)

Keywords: **Inflammatory bowel disease**, Crohn's disease, ulcerative colitis, ... levels at non-trough **time** points have also correlated with **clinical response**. In **patients** with controlled IBD activity on IFX, dose adjustment **can** also be beneficial. **Therapeutic** drug monitoring, mucosal healing, deep **remission**: the path to ...

缺少字词: **clinician expect told**

Withdrawal of anti-tumour necrosis factor α therapy in inflammatory ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)作者: K Papamichael - 2015 - 被引用次数: 9 - [相关文章](#)

2015年4月28日 - Keywords: **Inflammatory bowel disease**, Anti-tumour necrosis factor α therapy, ... Possible lower **response** rates after re-initiation of biological therapy, ... that a proportion of **patients**, in **clinical remission can** stop anti-TNF α ... definition of relapse and the (median) follow up **time** after anti-TNF α cessation[21].

缺少字词: **expect told**

Management of Crohn's Disease in Adults | American College of ...

<https://gi.org/guideline/management-of-crohn's-disease-in-adults/> > [翻译此页](#)

Associated extraintestinal features **can** include **inflammation** of the eyes, skin, or joints (see ... CD limited to the **colon can** be difficult to distinguish from ulcerative colitis (1). ... half of all **patients** being in **clinical remission** at any particular **time**. The **patients' response** to initial therapy **should** be

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 107,000 条结果 (用时 0.63 秒)

Progress in the Diagnosis and Treatment of Inflammatory Bowel Disease

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者: EV Loftus Jr - 2011 - 被引用次数: 4 - 相关文章

In UC, **intestinal inflammation** is typically restricted to the **colon**, but CD **can** ... these agents have a slow onset of action and a narrow **therapeutic** window. A high proportion of **patients** at Weeks 10 and 54 achieved IBDQ **response** ... **Clinical remission** (defined as Harvey-Bradshaw Index score ≤ 4) was **Time will tell**.

[Management of failure of infliximab in inflammatory bowel disease].

<https://www.ncbi.nlm.nih.gov/pubmed/21681712> - 翻译此页

作者: N Naija - 2011 - 被引用次数: 4 - 相关文章

[Management of failure of infliximab in **inflammatory bowel disease**]. ... the failure of infliximab is a real problem which **the clinician should** resolve quickly. ... of these during treatment significantly improves the **clinical response** of **patients**. Also, the increased **time** of exposure to infliximab, either by increasing doses or shorter ...

缺少字词: remission expect told

Loss of Response to Anti-TNFs: Definition, Epidemiology, and ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737871/> - 翻译此页

作者: G Roda - 2016 - 被引用次数: 22 - 相关文章

2016年1月7日 - In this paper we **will** provide an overview of the definition, epidemiology ... respond to the initial treatment and 23–46% of **patients** lose **response** over **time**. ... No anti-TNF antibodies present with sub-**therapeutic** drug level challenge for **clinicians** who manage **patients** with **inflammatory bowel diseases**.

缺少字词: expect told

Current and emerging drugs for the treatment of inflammatory bowel ...

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - 翻译此页

作者: JK Triantafillidis - 2011 - 被引用次数: 150 - 相关文章

2011年4月6日 - Keywords: **inflammatory bowel disease**, ulcerative colitis, Crohn's ... In this review we **will** try to describe the established and emerging **therapeutic** CSs are highly effective drugs for induction of **remission** in **patients** with active CD. The **clinical response** rates in steroid-dependent